Clinical Trial Update: Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial [Phase 3]

View source ↗

Summary

A randomized Phase 3 trial comparing high-dose versus lower-dose oxaliplatin-containing HAIC regimens combined with sorafenib or lenvatinib for unresectable adv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• 5-FU (5-fluorouracil)
• Lenvatinib (lenvatinib)
• Oxaliplatin HAIC (130 mg/m²) (oxaliplatin)
• Oxaliplatin HAIC (85 mg/m²) (oxaliplatin)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: UNKNOWN